RT Journal Article SR Electronic T1 Beyond antidoping and harm minimisation: a stakeholder-corporate social responsibility approach to drug control for sport JF Journal of Medical Ethics JO J Med Ethics FD BMJ Publishing Group Ltd and Institute of Medical Ethics SP 220 OP 223 DO 10.1136/medethics-2015-102661 VO 42 IS 4 A1 Jason Mazanov YR 2016 UL http://jme.bmj.com/content/42/4/220.abstract AB Debate about the ethics of drug control in sport has largely focused on arguing the relative merits of the existing antidoping policy or the adoption of a health-based harm minimisation approach. A number of ethical challenges arising from antidoping have been identified, and a number of, as yet, unanswered questions remain for the maturing ethics of applying harm minimisation principles to drug control for sport. This paper introduces a ‘third approach’ to the debate, examining some implications of applying a stakeholder theory of corporate social responsibility (CSR) to the issue of doping in sport. The introduction of the stakeholder-CSR model creates an opportunity to challenge the two dominant schools by enabling a different perspective to contribute to the development of an ethically robust drug control for sport.